Navigation Links
Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Raises Target Price to $3.22
Date:4/5/2011

SAN FRANCISCO, April 5, 2011 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Pro-Pharmaceuticals, Inc. (OTCBB: PRWP) ("the Company") and raised its twelve month target price to $3.22. Ross Silver, Principal Analyst at Vista Partners stated, "The Company stated that it has reached an agreement with the FDA on the design of a pivotal, randomized, controlled, and blinded Phase III clinical trial of DAVANAT®. We believe this to be a significant milestone in the Company's history and could open the door for a potential partnership." Mr. Silver continued, "The Company has stated that it plans to initiate a Phase I/ll clinical trial of DAVANAT® in combination with a melanoma vaccine in collaboration with the Ludwig Institute in Brussels, Belgium in the third quarter.  This collaboration to date has shown that DAVANAT® activates tumor-specific cytotoxic T-cells allowing them to kill tumor cells. In addition, the Company plans to obtain an IND for treatment of liver fibrosis in the fourth quarter and plans to initiate clinical trials in early 2012."  Mr. Silver concludes, "We believe Pro-Pharmaceuticals to be one of the most attractive small cap biotechnology companies we have come across as a result of its robust clinical pipeline, which includes two candidates entering the clinic later this year and a late stage clinical candidate for metastatic colorectal cancer, all of which would compete in multi-billion dollar markets if approved. In addition, the Company has a strong management team, which is led by CEO Dr. Peter Traber, the former Chief Medical Officer of GlaxoSmithKline plc."

To download a FREE copy of the Pro-Pharmaceuticals, Inc. research report, please visit http://www.vistapglobal.com and click the "download research" icon to gain access to the report.

About Vista Partners:

Vista Partners LLC was founded in 2005 and has offices in California and one in Oregon. Vista Partners LLC is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.

Disclaimer & Disclosure:

For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com or click here.

Contact:
877.215.4813 or info@vistapglobal.com


'/>"/>
SOURCE Vista Partners
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harris Corporation Awarded Contract to Provide Engineering and Enterprise Support to Veteran Affairss VistA Imaging System
2. Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis
3. Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Maintains Target Price of $2.10
4. New FORTEO® and EVISTA® Data to be Presented at Premiere Scientific Meeting for Bone and Mineral Research
5. Vista Partners Updates Coverage on Raptor Pharmaceutical Corp.
6. U.S. Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014
7. Chula Vistas Dr. Peter Rullan Adds Alma Lasers Pixel CO2 Laser System to Offer Fractional CO2 Laser Treatments to Patients
8. Biovista Announces the Appointment of Clifford H. Farrah to its Advisory Board
9. New High-Resolution Computer Tomography Data Demonstrates EVISTA(R)s Effect on Bone Quality in Osteoporotic Patients
10. Watson Confirms EVISTA(R) Patent Challenge
11. Biovista Inc. and FDA to Collaborate on a Medication Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , Mar 23, 2017 Research and ... Analysis & Trends - Industry Forecast to 2025" report to ... ... of around 6.9% over the next decade to reach approximately $3.5 ... estimates and forecasts for all the given segments on global as ...
(Date:3/23/2017)... , March 23, 2017 The ... ageing population, increasing diabetic population, accelerating economic growth and increasing ... this industry are higher life expectancy of ESRD patients, rising ... emerging markets. However, the expansion of the market is hindered ... ...
(Date:3/23/2017)... , March 23, 2017  Transportation Insight, a multi-modal ... end-to-end supply chain management firm with expertise serving clients ... Solutions Rick Zaffarano was named a 2017 ... Supply Chain by the only publication exclusively dedicated to ... supply chain. "Rick has brought to Transportation ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, ... their training and leads programs. , In February, 2017, Empower Brokerage introduced their ... Performance Partners is designed to teach how to maximize their sales efforts, as ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding Christ Through Social Media: ... journal chronicling the writer’s path toward true communion with God. “Finding Christ Through ... is the creation of published author Lea Michelle Johnson, a follower of Christ, ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... “Vintage and ... a retired minister and college Bible teacher residing in North Carolina with his wife, ... who have blessed them with six grandchildren. David is also the author of “Shadow ...
(Date:3/24/2017)... ... ... “The Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story ... fullest, as God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” ... passion for writing, especially about truth and human behavior. , Published by Christian Faith ...
(Date:3/23/2017)... ... ... A recent report from the National Council on Teacher Quality (NCTQ) advocates for ... on a review of GPA and SAT/ACT requirements at 221 institutions in 25 states, ... that this higher bar should be set by states, by the Council for the ...
Breaking Medicine News(10 mins):